Compare CMRE & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | TWST |
|---|---|---|
| Founded | 1974 | 2013 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2010 | 2018 |
| Metric | CMRE | TWST |
|---|---|---|
| Price | $16.28 | $34.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $12.00 | ★ $44.88 |
| AVG Volume (30 Days) | 460.3K | ★ 1.1M |
| Earning Date | 02-04-2026 | 02-02-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $2,085,335,000.00 | $376,572,000.00 |
| Revenue This Year | N/A | $15.19 |
| Revenue Next Year | N/A | $15.10 |
| P/E Ratio | $6.51 | ★ N/A |
| Revenue Growth | ★ 79.87 | 20.32 |
| 52 Week Low | $6.63 | $23.30 |
| 52 Week High | $16.40 | $55.33 |
| Indicator | CMRE | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 64.21 | 57.35 |
| Support Level | $15.27 | $31.00 |
| Resistance Level | $16.01 | $37.73 |
| Average True Range (ATR) | 0.36 | 1.67 |
| MACD | -0.01 | 0.26 |
| Stochastic Oscillator | 90.59 | 56.02 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.